I've also done some research on Yeast artificial 'CBD' through genetically altered yeast which has some fairly good developments out of the Berkley college in California, still a bit expensive for standardizing a production line from scratch but the setups Stil is creating provide most of the integral parts of a production line needing different vat setups, at the 'front of the line'... and of course lots of fine tuning moving down the line.
To say, with access to a "proprietary" yeast strain(genetically altered), there doesn't seem any impossible hurdles to Stil using a Yeast production should marketing move in that direction based on having a ongoing operation.(The Stil employee/Affectionately I refer to as 'The Beer maker', can 'pipeline' this.
Far in advance from current status now.. it seems to me three major potentials in the 'Pharma applications' present themselves for year 2021.
We will see what we see, but a proprietary production setup buyout on each of 'my 3 particular interests CBD molecules wise' I imagine should be worth, in ongoing, about 1/2 billion? apiece. Done 'properly' about 5$ per share without much to do with distribution, or with, be simply additives to the previous 3 lines of development.. without buyouts, without Pharmaceutical qualifying medical claims will still be a very highly attractive content for a seller of said 3 lines.
Cancer cell killer.
LDL inhibitor.
A simple alternative to aspirin(NSAIDs).
We will know somewhere in 4th quarter, 4th quarter started 2 days ago:), by way of cash flow from sales or not, much of going forward potentials.
Gotta get those first dollars into the 'Register'.
